But the Trump administration’s cuts to HIV programs in the U.S. and abroad could undermine the drug’s rollout.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

The drug could change the course of the AIDS epidemic. But the Trump administration has gutted the programs that might have paid for it in low-income countries.